A global treatments for coronaviruses including COVID-19.
COVID-19
antiviral
coronavirus
drug
treatment
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
15
04
2020
accepted:
03
05
2020
pubmed:
13
5
2020
medline:
8
10
2020
entrez:
13
5
2020
Statut:
ppublish
Résumé
In late December 2019 in Wuhan, China, several patients with viral pneumonia were identified as 2019 novel coronavirus (2019-nCoV). So far, there are no specific treatments for patients with coronavirus disease-19 (COVID-19), and the treatments available today are based on previous experience with similar viruses such as severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Influenza virus. In this article, we have tried to reach a therapeutic window of drugs available to patients with COVID-19. Cathepsin L is required for entry of the 2019-nCoV virus into the cell as target teicoplanin inhibits virus replication. Angiotensin-converting-enzyme 2 (ACE2) in soluble form as a recombinant protein can prevent the spread of coronavirus by restricting binding and entry. In patients with COVID-19, hydroxychloroquine decreases the inflammatory response and cytokine storm, but overdose causes toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and zanamivir are invalid for 2019-nCoV and are not recommended for treatment but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the progression of MERS-CoV disease and can be useful for patients of COVID-19 and, in combination with Arbidol, has a direct antiviral effect on early replication of SARS-CoV. Ribavirin reduces hemoglobin concentrations in respiratory patients, and remdesivir improves respiratory symptoms. Use of ribavirin in combination with LPV/r in patients with SARS-CoV reduces acute respiratory distress syndrome and mortality, which has a significant protective effect with the addition of corticosteroids. Favipiravir increases clinical recovery and reduces respiratory problems and has a stronger antiviral effect than LPV/r. currently, appropriate treatment for patients with COVID-19 is an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids.
Identifiants
pubmed: 32394467
doi: 10.1002/jcp.29785
pmc: PMC7273044
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9133-9142Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Sci Rep. 2017 Mar 06;7:43395
pubmed: 28262699
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Curr Med Chem. 2008;15(10):997-1005
pubmed: 18393857
Immunol Rev. 1993 Dec;136:5-28
pubmed: 7907572
J Thorac Oncol. 2020 May;15(5):700-704
pubmed: 32114094
J Feline Med Surg. 2019 Apr;21(4):271-281
pubmed: 30755068
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Antiviral Res. 2018 May;153:85-94
pubmed: 29524445
J Cell Physiol. 2020 Dec;235(12):9133-9142
pubmed: 32394467
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Clin Sci (Lond). 2020 Mar 13;134(5):543-545
pubmed: 32167153
Drugs. 2000 Dec;60(6):1371-9; discussion 1380-1
pubmed: 11152017
Pharmacol Ther. 2020 May;209:107512
pubmed: 32097670
Virology. 2002 Dec 20;304(2):211-21
pubmed: 12504563
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Antiviral Res. 2018 Jan;149:143-149
pubmed: 29175128
Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Feb;37(2):291-3
pubmed: 26917533
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Int J Antimicrob Agents. 2020 May;55(5):105938
pubmed: 32171740
Virology. 2020 Jun;545:1-9
pubmed: 32174453
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
F1000Res. 2020 Jan 31;9:72
pubmed: 32117569
Nat Med. 2013 Oct;19(10):1313-7
pubmed: 24013700
J Infect. 2020 Jul;81(1):e1-e5
pubmed: 32171872
Medicine (Baltimore). 2015 Jul;94(27):e1070
pubmed: 26166080
Lancet Infect Dis. 2020 Oct;20(10):1204-1214
pubmed: 32526195
J Infect Dis. 2010 Oct 15;202(8):1154-60
pubmed: 20831384
Antimicrob Agents Chemother. 2000 Apr;44(4):859-66
pubmed: 10722482
Cell Res. 2013 Feb;23(2):300-2
pubmed: 23208422
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
J Korean Med Sci. 2020 Feb 17;35(6):e79
pubmed: 32056407
BMC Microbiol. 2003 Dec 21;3:25
pubmed: 14687413
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
Curr Opin Virol. 2013 Apr;3(2):180-4
pubmed: 23273851
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
J Virol. 2015 Dec 30;90(6):3253-6
pubmed: 26719272
J Virol. 2019 May 29;93(12):
pubmed: 30918074
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
J Infect. 2013 Dec;67(6):606-16
pubmed: 24096239
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Int J Infect Dis. 2020 Jun;95:183-191
pubmed: 32173576
Nat Commun. 2020 Apr 24;11(1):2070
pubmed: 32332765
Clin Infect Dis. 2019 Mar 5;68(6):e1-e47
pubmed: 30566567
Signal Transduct Target Ther. 2020 Feb 21;5(1):18
pubmed: 32296012
Rev Med Virol. 2006 Jan-Feb;16(1):37-48
pubmed: 16287208
Gastroenterology. 2006 Nov;131(5):1452-62
pubmed: 17101321
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463
pubmed: 28769016
Vopr Virusol. 2008 Jul-Aug;53(4):9-13
pubmed: 18756809
Medicine (Baltimore). 2019 Jun;98(26):e16239
pubmed: 31261585
Antiviral Res. 2018 Feb;150:155-163
pubmed: 29289665
Clin Infect Dis. 2020 Oct 23;71(7):e191-e194
pubmed: 32124919
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Dent Assist. 2006 Mar-Apr;75(2):4-9; quiz 10-1
pubmed: 16696496
Lancet Infect Dis. 2006 Feb;6(2):67-9
pubmed: 16439323
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32152082
Clin Infect Dis. 2020 Aug 14;71(4):1089-1091
pubmed: 31538643
J Immunol. 1998 Apr 1;160(7):3487-93
pubmed: 9531310